Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0N8QK
|
||||
| Former ID |
DNCL001986
|
||||
| Drug Name |
ABT-288
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Alzheimer disease; Schizophrenia [ICD9: 331, 295; ICD10:G30, F20] | Phase 2 | [1], [2] | ||
| Company |
Abbott Laboratories
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C23H24N4O
|
||||
| InChI |
InChI=1S/C23H24N4O/c1-25-15-19-12-14-26(22(19)16-25)20-8-4-17(5-9-20)18-6-10-21(11-7-18)27-23(28)3-2-13-24-27/h2-11,13,19,22H,12,14-16H2,1H3/t19-,22+/m1/s1
|
||||
| InChIKey |
GNIRITULTPTAQW-KNQAVFIVSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Histamine H3 receptor | Target Info | Modulator | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Reactome | Histamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Monoamine Transport | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01018875) Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease. U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6927). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.